According to Brazil's Butantan biomedical center, the COVID-19 vaccine developed by China's Sinovac Biotech has been found to be just 50.4 percent effective in Brazilian clinical trials. The number is significantly lower than the efficacy levels previously reported. However, Sinovac CEO Yin Weidong says the reports of lower efficacy rate are misleading.